Seminars in Nuclear Medicine
Volume 34, Issue 3 , Pages 198-208 , July 2004

Neoplasms of the esophagus and stomach

  • Farrokh Dehdashti

      Affiliations

    • Division of Nuclear Medicine, Edward Mallinckrodt Institute of Radiology and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA
    • Corresponding Author InformationAddress reprint requests to Farrokh Dehdashti, MD, Division of Nuclear Medicine, Edward Mallinckrodt Institute of Radiology, 510 S. Kingshighway Boulevard, St. Louis, MO 63110 USA
    • ,
  • Barry A Siegel

      Affiliations

    • Division of Nuclear Medicine, Edward Mallinckrodt Institute of Radiology and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA

References 

  1. Jemal A, Tiwari RC, Murray T, et al.  Cancer Statistics, 2004. CA Cancer J Clin. 2004;54:8–29
  2. Vermund H, Pories WJ, Hillard J, et al.  Neoadjuvant chemoradiation therapy in patients with surgically treated esophageal cancer. Acta Oncol. 2001;40:558–565
  3. Romagnuolo J, Scott J, Hawes RH, et al.  Helical CT versus EUS fine needle aspiration for celiac nodal assessment in patients with esophageal cancer. Gastrointest Endosc. 2002;55:648–654
  4. Wren SM, Stijns P, Srinivas S. Positron emission tomography in the initial staging of esophageal cancer. Arch Surg. 2002;137:1001–1006
  5. Kumbasar B. Carcinoma of esophagus (Radiologic diagnosis and staging). Eur J Radiol. 2002;42:170–180
  6. Fickling WE, Wallace MB. Endoscopic ultrasound and upper gastrointestinal disorders. J Clin Gastroenterol. 2003;36:103–110
  7. Lerut T, Coosemans W, Decker G, et al.  Cancer of the esophagus and gastro-esophageal junction (Potentially curative therapies). Surg Oncol. 2001;10:113–122
  8. Flanagan FL, Dehdashti F, Siegel BA, et al.  Staging of esophageal cancer with FDG-PET. AJR. 1997;168:417–424
  9. Block MI, Sundaresan SR, Patterson GA, et al.  Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg. 1997;64:770–777
  10. Kole AC, Plukker JT, Nieweg OE, et al.  Positron emission tomography for staging oesophageal and gastroesophageal malignancy. Br J Cancer. 1998;74:521–527
  11. Luketich JD, Schauer P, Meltzer CC, et al.  The role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg. 1997;64:765–769
  12. Rankin SC, Taylor H, Cook GJR, et al.  Computed tomography and positron emission tomography in the pre-operative staging of oesophageal carcinoma. Clin Radiol. 1998;53:659–665
  13. McAteer D, Wallis F, Couper G, et al.  Evaluation of 18F-FDG positron emission tomography in gastric and oesophageal carcinoma. Br J Radiol. 1999;72:525–529
  14. Yeung HWD, Macapinlac HA, Mazumdar M, et al.  FDG-PET in esophageal cancer (incremental value over computed tomography). Clin Pos Imaging. 1999;5:255–260
  15. Flamen P, Lerut A, Van Cutsem E, et al.  Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000;18:3202–3210
  16. Meltzer CC, Luketich JD, Friedman D, et al.  Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography. Clin Nucl Med. 2000;25:882–887
  17. Fukunaga T, Okazumi S, Koide Y, et al.  Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J Nucl Med. 1998;39:1002–1007
  18. Himeno S, Yasuda S, Shimada H, et al.  Evaluation of esophageal cancer by positron emission tomography. Jpn J Clin Oncol. 2002;32:340–346
  19. Dhar DK, Tachibana M, Kinukawa N, et al.  The prognostic significance of lymph node size in patients with squamous esophageal cancer. Ann Surg Oncol. 2002;9:1010–1016
  20. Lerut T, Flamen P, Ectors N, et al.  Histopathologic validation of lymph node staging with FDG-PET scan in cancer of esophagus and gastroesophageal junction (A prospective study based on primary surgery with extensive lymphadenectomy). Ann Surg. 2000;232:743–752
  21. Kim K, Park SJ, Kim BT, et al.  Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography. Ann Thorac Surg. 2001;71:290–294
  22. Luketich JD, Friedman DM, Weigel TL, et al.  Evaluation of distant metastases in esophageal cancer (100 consecutive positron emission tomography scans). Ann Thorac Surg. 1999;68:1133–1137
  23. Schöder H, Erdi YE, Larson SM, et al.  PET/CT (a new imaging technology in nuclear medicine). Eur J Nucl Med. 2003;30:1419–1437
  24. Bar-Shalom R, Yefremov N, Guralnik L, et al.  Clinical performance of PET/CT in evaluation of cancer (Additional value for diagnostic imaging and patient management). J Nucl Med. 2003;44:1200–1209
  25. Bar-Shalom R, Leiderman M, Gaitini D, et al.  The value of PET/CT using FDG in patients with esophageal cancer. J Nucl Med. 2003;44:21; (abstr)
  26. Wallace MB, Nietert PJ, Earle C, et al.  An analysis of multiple staging management strategies for carcinoma of the esophagus (Computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy). Ann Thorac Surg. 2002;74:1026–1032
  27. Law S, Fok M, Chow S, et al.  Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus (A perspective randomized trial). J Thorac Cardiovasc Surg. 1997;114:210–217
  28. Jones DR, Parker LA, Detterbeck FC, et al.  Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer. 1999;85:1026–1032
  29. Weber WA, Ott K, Becker K, et al.  Prediction of response to preoperative chemotherapy in adenocarcinomas of esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058–3065
  30. Downey RJ, Akhurst T, Ilson D, et al.  Whole body 18FDG-PET and the response of esophageal cancer to induction therapy (results of a prospective trial). J Clin Oncol. 2003;21:428–432
  31. Couper GW, McAteer D, Wallis F, et al.  Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer. Br J Surg. 1998;85:1403–1406
  32. Kato H, Kuwano H, Nakajima M, et al.  Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg. 2002;184:279–283
  33. Kroep JR, Van Grroeningen CJ, Cuesta MA, et al.  positron emission tomography using 2-deoxy-2-18F]-fluoro-D-glucose for response monitoring in locally gastroesophageal cancer (A comparison of different analytic methods). Mol Imaging Biol. 2003;5:337–346
  34. Brücher BLDM, Weber W, Bauer M, et al.  Neoadjuvant therapy of esophageal squamous cell carcinoma (Response evaluation by positron emission tomography). Ann Surg. 2001;233:300–309
  35. Arslan N, Miller TR, Dehdashti F, et al.  Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer. Mol Imaging Biol. 2002;4:320–329
  36. Fukunaga T, Enomoto K, Okazumi S, et al.  Analysis of glucose metabolism in patients with esophageal cancer by PET (Estimation of hexokinase activity in the tumor and usefulness for clinical assessment using FDG). Nippon Geka Gakka Zasshi. 1994;95:317–325
  37. Flamen P, Lerut A, Van Cutsem E, et al.  The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg. 2000;120:1085–1092
  38. Chan AO, Wong BC, Lam SK. Gastric cancer (Past, present and future). Can J Gastroenterol. 2001;15:469–474
  39. Yeung HWD, Macapinlac HA, Karpeh M, et al.  Accuracy of FDG-PET in gastric cancer (Preliminary experience). Clin Pos Imaging. 1999;4:213–221
  40. Stah A, Ott K, Weber WA, et al.  FDG-PET imaging of locally advanced gastric carcinomas (correlation with endoscopic and histological findings). Eur J Nucl Med. 2003;30:288–295
  41. Berger KL, Nicholson SA, Dehdashti F, et al.  FDG-PET evaluation of mucinous neoplasms (Correlation of FDG uptake with histopathologic features). AJR. 2000;174:1005–1008
  42. Yoshioka T, Yamaguchi K, Kubota K, et al.  Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med. 2003;44:690–699
  43. De Potter T, Flamen P, Van Cutsem E, et al.  Whole-body PET imaging for the diagnosis of recurrent gastric cancer. Eur J Nucl Med. 2002;29:525–529

PII: S0001-2998(04)00023-6

doi: 10.1053/j.semnuclmed.2004.03.005

Seminars in Nuclear Medicine
Volume 34, Issue 3 , Pages 198-208 , July 2004

Article Tools

* Image Usage & Resolution